CorrespondenceBaricitinib for systemic lupus erythematosus
References (4)
- et al.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Lancet
(2018) FDA approves Eli Lilly's baricitinib
Nat Rev Drug Discov
(2018)
Cited by (9)
Systemic Autoinflammatory Diseases: A Growing Family of Disorders of Overlapping Immune Dysfunction
2022, Rheumatic Disease Clinics of North AmericaCitation Excerpt :IL-1 inhibition in more complex disorders exemplifies this concept with the recognition of the central role of inflammasomes and the IL-1 family of cytokines in disorders, such as sJIA, gout, Behçet disease, macrophage activation syndrome, and cytokine storm syndromes.4,58 The discovery that polygenic autoimmune disorders (e.g., systemic lupus erythematosus [SLE]) feature type I IFN overactivation has triggered the investigation of IFN inhibition in their treatment.59 In addition, the localized manifestations of SAIDs involving dysregulation of the IL-1 family in diseases, such as deficiency of IL-1 receptor antagonist (DIRA), deficiency of IL-36 receptor antagonist (DITRA), Majeed syndrome, and CARD 14–mediated pustular psoriasis (CAMPS), also have provided important insights into the role of those mediators in the homeostasis of local tissues (e.g., keratinocytes and epithelia),25 and, remarkably, the discovery of IL-1 dysregulation in atherosclerosis has triggered investigations of the role of IL-1 in cardiovascular diseases.42
Current and future status of JAK inhibitors
2021, The LancetCitation Excerpt :Serious adverse events were seen in 9·6% of patients in the baricitinib 4 mg group versus 4·8% in the placebo group. As raised by Yuan and colleagues70 in response to the study, the 4 mg dosing strategy of baricitinib was not approved by the FDA for rheumatoid arthritis due to safety concerns of potential infectious and thrombotic complications, hence additional follow-up and more knowledge are required for this dosing regimen. Two dosing strata are being explored in the phase 3 trial, BRAVE II, with an ongoing long-term follow-up study from the earlier trials (SLE-BRAVE-X; NCT03843125).
Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders
2020, European Journal of Medicinal ChemistryCitation Excerpt :There were also no notable safety concerns and the predefined secondary endpoints of SLE Responder Index-4 response, Lupus Low Disease Activity Score and flares of any severity were significantly improved in the Baricitinib 4 mg group versus the placebo group. This first trial and the positive findings indicate that 3 could be a favorable drug for SLE [77]. 3 is also applied for the treatment of Atopic Dermatitis (AD) which is the most common chronic inflammatory skin disease.
Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application
2021, Current Drug Research Reviews